Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia

NCT00804856 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00804856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00804856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2008
Completion date
April 23, 2021
Enrollment
180 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute